Tag:
Glenmark Pharmaceuticals
Latest Headlines
Latest Headlines
Sanofi forges $663M MS antibody development pact with Glenmark
India's biotech companies are beginning to make their mark in the antibody development field. Sanofi has inked a $663 million development pact with India's Glenmark Pharmaceuticals, proffering $50
Glenmark touts (much needed) $345M pain pact with Sanofi
Shares of India's Glenmark jumped on the news that Sanofi-Aventis has signed up for a $345 million partnership to develop new pain drugs. Glenmark gets $20 million upfront in the deal, along with
Forbes profiles Glenmark's R&D moves
Forbes profiles Glenmark Pharmaceuticals, the Indian drugmaker that's making the switch from a generics company to an innovative drug developer. CEO Glenn Saldanha has a strategy: develop new drugs
Glenmark, Forest Labs COPD therapy fails mid-stage trial
In another setback for its plans to develop a range of new drugs, India's Glenmark Pharmaceuticals and its U.S. partner Forest Laboratories revealed that their experimental COPD drug failed a Phase
Lilly, Glenmark suspend osteoporosis trial
In a release, India's Glenmark Pharmaceuticals said its partner Eli Lilly has suspended further clinical development for GRC 6211 for osteoarthritis pain. The companies didn't give an explanation for
India eyes R&D opportunities
India-based drugs have made a name for themselves as makers of copycat drugs. When a developer's lucrative drug goes off-patent, Indian companies are guaranteed to swoop in and make a less-expensive
